크론병 또는 궤양성 대장염 환자를 대상으로 발리나툰피브의 장기 안전성, 내약성 및 효능을 조사하는 연구(SPECIFI-IBD-LTS)
발리나툰핍을 투여하는 크론병 또는 궤양성 대장염 성인 환자를 대상으로 장기간 안전성, 내약성 및 효능을 조사하기 위한 다국적, 다기관 연장 연구
LTS19689 is a multinational, multicenter extension study to evaluate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn's disease (CD) or ulcerative colitis (UC) who completed the 52-week treatment period (on balinatunfib or placebo) in the parent studies, SPECIFI-CD (DRI18212) or SPECIFI-UC (DRI17822), respectively.
-
The primary objective of this study is to assess the long-term safety and tolerability of different doses of balinatunfib in participants with CD or UC, as measured by the number and percentage of participants with CD or UC with treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events of special interest (AESIs) during the study period.
-
The study will consist of 2 independent cohorts through the study given the distinct nature of each disease:
- CD Cohort: comprised of CD participants enrolled from SPECIFI-CD (DRI18212).
- UC Cohort: comprised of UC participants enrolled from SPECIFI-UC (DRI17822).
-
The study will consist of the following study periods for each cohort:
-
A Double-Blind (DB) treatment period of up to 104 weeks for eligible participants from the DB maintenance phases of the respective parent studies.
-
An Open-Label (OL) treatment period of up to 104 weeks for:
- Eligible participants from either the DB or OL periods of the parent studies,
- Eligible participants who meet escape criteria at any time during the DB period of the LTS19689.
-
A 2-week follow-up period following the End of Treatment (EOT). The study duration will be up to 107 weeks, with the treatment duration up to 104 weeks.
-
연구 개요
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Texas
-
Southlake, Texas, 미국, 76092
- Texas Digestive Disease Consultants - Southlake- Site Number : 8400005
-
-
-
-
-
Gorna Oryahovitsa, 불가리아, 5100
- Investigational Site Number : 1000001
-
-
-
-
-
Buenos Aires, 아르헨티나, 1061
- Investigational Site Number : 0320001
-
-
-
-
Milano
-
Milan, Milano, 이탈리아, 20132
- Investigational Site Number : 3800002
-
-
-
-
-
Guangzhou, 중국, 510080
- Investigational Site Number : 1560002
-
Shanghai, 중국, 200120
- Investigational Site Number : 1560032
-
-
-
-
-
Olomouc, 체코, 779 00
- Investigational Site Number : 2030001
-
-
-
-
Reg Metropolitana de Santiago
-
Santiago, Reg Metropolitana de Santiago, 칠레, 8331143
- Investigational Site Number : 1520010
-
Santiago, Reg Metropolitana de Santiago, 칠레, 7500010
- Investigational Site Number : 1520016
-
Santiago, Reg Metropolitana de Santiago, 칠레, 8380456
- Investigational Site Number : 1520012
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Participants are eligible to be included in the study only if all of the following criteria apply:
-
Participants with Crohn's Disease (CD) or ulcerative colitis (UC) who completed treatment at Week 52 of the SPECIFI-CD (DRI18212) or SPECIFI-UC (DRI17822) studies, respectively:
-
Participants with CD
-
who complete double-blinded treatment at Week 52 of SPECIFI-CD (DRI18212) study;
-
who complete open label treatment and achieve the appropriate outcomes at Week 52 of SPECIFI-CD (DRI18212) study.
OR
-
-
Participants with UC
- who complete double-blinded treatment at Week 52 of SPECIFI-UC (DRI17822) study;
- who complete open label treatment and achieve the appropriate outcomes at Week 52 of the SPECIFI-UC (DRI17822) study.
-
-
Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Women participants should not be pregnant or breastfeeding
Exclusion Criteria:
- Participants with CD who develop a new medical condition precluding participation as described in Exclusion criteria of SPECIFI-CD (DRI18212) clinical trial protocol.
- Participants with UC who develop a new medical condition precluding participation as described in Exclusion criteria of SPECIFI-UC (DRI17822) clinical trial protocol.
- Participants who developed a new medical condition or a change in status of an established medical condition which (per Investigator's medical judgment) would adversely affect the participation in this study or would require permanent IMP discontinuation.
- Participants who permanently discontinued IMP during the parent study or temporarily discontinued IMP for more than 14 consecutive calendar days by the time of Day 1 of LTS19689.
- Participants who, during their participation in the parent study, developed an adverse event (AE) or a serious adverse event (SAE) deemed related to balinatunfib, which in the opinion of the Investigator could indicate that continued treatment with balinatunfib may present an unreasonable risk for the participant.
- Participants who in the parent study had documented nonadherence to IMP or to standard therapies for CD or UC, or who used a prohibited medication concomitant with IMP or during a temporary IMP discontinuation period.
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: CD cohort: balinatunfib dose regimen 1
Participants will receive balinatunfib dose regimen 1 |
Pharmaceutical form:Tablet -Route of administration:Oral
다른 이름들:
|
|
실험적: CD cohort: balinatunfib dose regimen 2
Participants will receive balinatunfib dose regimen 2 |
Pharmaceutical form:Tablet -Route of administration:Oral
다른 이름들:
|
|
실험적: CD cohort: balinatunfib dose regimen 3
Participants will receive balinatunfib dose regimen 3 |
Pharmaceutical form:Tablet -Route of administration:Oral
다른 이름들:
|
|
위약 비교기: CD cohort: Placebo
Participants will receive balinatunfib-matching placebo |
Pharmaceutical form:Tablet -Route of administration:Oral |
|
실험적: UC cohort: balinatunfib dose regimen 1
Participants will receive balinatunfib dose regimen 1 |
Pharmaceutical form:Tablet -Route of administration:Oral
다른 이름들:
|
|
실험적: UC cohort: balinatunfib dose regimen 2
Participants will receive balinatunfib dose regimen 2 |
Pharmaceutical form:Tablet -Route of administration:Oral
다른 이름들:
|
|
실험적: UC cohort: balinatunfib dose regimen 3
Participants will receive balinatunfib dose regimen 3 |
Pharmaceutical form:Tablet -Route of administration:Oral
다른 이름들:
|
|
위약 비교기: UC cohort: Placebo
Participants will receive balinatunfib-matching placebo |
Pharmaceutical form:Tablet -Route of administration:Oral |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
크론병 환자에서 치료 중 발생한 이상사례(TEAE), 중대한 이상사례(SAE) 및 특별 관심 이상사례(AESI)가 발생한 참가자 수
기간: 연구 종료 시점까지(약 106주)
|
연구 종료 시점까지(약 106주)
|
|
치료 중 발현된 이상사례(TEAE), 중대한 이상사례(SAE) 및 특별 관심 이상사례(AESI)가 발생한 궤양성 대장염 참가자 수
기간: 연구 종료 시까지(약 106주)
|
연구 종료 시까지(약 106주)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Proportion of participants with Crohn's Disease in endoscopic remission based on simple endoscopic score for Crohn's disease (SES-CD)
기간: Week 52
|
Endoscopic remission is defined as SES-CD ≤4 points (SES CD ≤2 points for isolated ileal disease) and a SES-CD decrease ≥2 points with no SES-CD subscore >1 point from baseline. The SES-CD evaluates 4 endoscopic items (ulcer size, ulcerated surface, affected surface, and narrowing, each on a scale from 0 (none) to 3 in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and ranges from 0 to 56, where higher scores indicate more severe disease. |
Week 52
|
|
Proportion of participants with Crohn's Disease in endoscopic remission based on simple endoscopic score for Crohn's disease (SES-CD)
기간: Week 104
|
Endoscopic remission is defined as SES-CD ≤4 points (SES CD ≤2 points for isolated ileal disease) and a SES-CD decrease ≥2 points with no SES-CD subscore >1 point from baseline. The SES-CD evaluates 4 endoscopic items (ulcer size, ulcerated surface, affected surface, and narrowing, each on a scale from 0 (none) to 3 in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and ranges from 0 to 56, where higher scores indicate more severe disease. |
Week 104
|
|
Proportion of participants with Crohn's Disease in clinical remission based on Crohn's disease activity index (CDAI)
기간: Week 52
|
Clinical remission is defined as CDAI <150. The CDAI score is composed of eight items: 3 of them (abdominal pain, stool frequency and general well-being) completed by the participant and the others (use of anti-diarrheal medications, extraintestinal complications, palpable abdominal mass, hematocrit levels, and body weight) assessed and reported by the clinician. The CDAI is derived from summing up the weighted individual scores of eight items. Scores on the CDAI scale range from 0 to 600, with higher scores indicating more severe disease. |
Week 52
|
|
Proportion of participants with Crohn's Disease in clinical remission based on Crohn's disease activity index (CDAI)
기간: Week 104
|
Clinical remission is defined as CDAI <150. The CDAI score is composed of eight items: 3 of them (abdominal pain, stool frequency and general well-being) completed by the participant and the others (use of anti-diarrheal medications, extraintestinal complications, palpable abdominal mass, hematocrit levels, and body weight) assessed and reported by the clinician. The CDAI is derived from summing up the weighted individual scores of eight items. Scores on the CDAI scale range from 0 to 600, with higher scores indicating more severe disease. |
Week 104
|
|
Proportion of participants with ulcerative colitis in clinical remission based on modified Mayo Score (mMS)
기간: Week 52
|
Clinical remission by modified Mayo score (mMS) is defined as a mMS score of 0 to 2, including stool frequency (SF) of 0 or 1, rectal bleeding (RB) subscore of 0, and centrally read modified Mayo Endoscopic Subscore [mMES] of 0 or 1 (score of 1 modified to exclude friability).Each component of the mMS (SF, RB, and mMES) is scored from 0 to 3. The total mMS ranges from 0 to 9 with higher scores indicating greater disease severity |
Week 52
|
|
Proportion of participants with ulcerative colitis in clinical remission based on modified Mayo Score (mMS)
기간: Week 104
|
Clinical remission by modified Mayo score (mMS) is defined as a mMS score of 0 to 2, including stool frequency (SF) of 0 or 1, rectal bleeding (RB) subscore of 0, and centrally read modified Mayo Endoscopic Subscore [mMES] of 0 or 1 (score of 1 modified to exclude friability).Each component of the mMS (SF, RB, and mMES) is scored from 0 to 3. The total mMS ranges from 0 to 9 with higher scores indicating greater disease severity |
Week 104
|
공동 작업자 및 조사자
스폰서
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- LTS19689
- 2025-522511-42 (레지스트리 식별자: CTIS)
- U1111-1321-1765 (레지스트리 식별자: WHO ICTRP)
- 2025 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .